Atika Capital Management’s Pacira BioSciences PCRX Stock Holding History

Atika Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-31,000	Closed	-$1.41M	–	85
2017 Q1	$1.41M	Buy	+31,000	New	+$1.34M	0.69%	52
2016 Q1	–	Sell	-64,000	Closed	-$4.91M	–	55
2015 Q4	$4.91M	Buy	+64,000	New	+$3.62M	2.53%	14
2014 Q4	–	Sell	-21,500	Closed	-$2.08M	–	76
2014 Q3	$2.08M	Sell	21,500 -1,500	-7%	-$146K	1.6%	27
2014 Q2	$2.11M	Sell	23,000 -12,000	-34%	-$914K	1.72%	23
2014 Q1	$2.45M	Buy	35,000 +12,000	+52%	+$816K	2.09%	16
2013 Q4	$1.32M	Buy	+23,000	New	+$1.21M	1.18%	34

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Atika Capital Management's PCRX Position: Q2 2017 in Review

Atika Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 31,000 shares — an estimated $1.41M sold.

Atika Capital Management first reported a position in PCRX in Q4 2013 and held it in 6 quarters. The position peaked at $4.91M in Q4 2015. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

Atika Capital Management reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
Atika Capital Management sold 31,000 Pacira BioSciences shares in Q2 2017, an estimated $1.41M.
Atika Capital Management first reported a position in Pacira BioSciences in Q4 2013 and held it in 6 quarters.
Atika Capital Management's Pacira BioSciences position peaked at $4.91M in Q4 2015.
196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Atika Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.